Use code WELCOME25 on your first order • Buy 5 peptides, get 1 FREE

PNC-27

PNC-27 is a synthetic 32-amino acid chimeric peptide that combines the HDM-2 binding domain from p53 (residues 12-26) with a membrane-penetrating sequence. Researchers became interested when early studies revealed something unexpected: this peptide could selectively induce rapid cancer cell death across multiple cancer types while leaving normal cells completely unaffected—a selectivity driven by differential HDM-2 expression in cancer versus normal cell membranes.

$99.99

30 in stock

🎁 Buy 5 peptides, get 1 FREE  ·  10 → 1 premium free  ·  15 → 2 free  ·  20 → 3 free
FREE Bac Water when you check out with Zelle, Venmo or Cash App — added automatically.
SKU pnc-275mg Categories ,

5

6

Description

How It Works (What Makes It Interesting)

Studies suggest PNC-27 induces selective cancer cell death through several interconnected mechanisms:

  • Membrane HDM-2 targeting – Binds specifically to HDM-2 protein that cancer cells (but not normal cells) express on their plasma membranes, creating the foundation for selective cytotoxicity
  • Transmembrane pore formation – Forms ring-shaped pore structures in cancer cell membranes upon HDM-2 binding, causing rapid membranolysis and cell contents extrusion
  • Necrotic cell death pathway – Induces necrosis rather than apoptosis, bypassing resistance mechanisms that cancer cells often develop against apoptosis-inducing agents
  • Mitochondrial disruption – Penetrates cancer cells and disrupts mitochondrial membranes, creating a dual-targeting effect on both plasma and organelle membranes
  • p53-independent action – Functions effectively in cancer cells with deleted, mutated, or overexpressed p53, expanding research applications beyond p53-functional cancers

Common Research Applications

Pancreatic Cancer Models: MIA-PaCa-2 cell lines, TUC-3 metastatic pancreatic cancer, k-ras-transformed pancreatic cancer, pancreatic adenocarcinoma xenografts

Breast Cancer Research: MCF-7 cells, MDA-MB-468 (mutant p53), MDA-MB-157 (p53-null), triple-negative breast cancer models, metastatic breast cancer lines

Hematological Malignancies: Acute myeloid leukemia (U937, OCI-AML3, HL60), chronic myeloid leukemia (K562), acute promyelocytic leukemia, stem-cell lineage leukemia models

Melanoma Studies: A-2058 melanoma cell lines, metastatic melanoma models, drug-resistant melanoma research

Gynecological Cancer Models: Ovarian cancer, endometrial cancer, epithelial ovarian carcinoma, cervical carcinoma research

Other Solid Tumor Research: Lung carcinoma, colon adenocarcinoma, osteosarcoma, p53-deficient cancer models, chemotherapy-resistant cancer line.

Independent lab report: a sample of this product was tested by Kovera Labs (June 2026). View the certificate of analysis. Reports apply only to the sample tested. For laboratory research use only.

Please confirm

You must be of legal age to enter this site.

WARNING: This website contains age-restricted content.